DPP4 and type 1 diabetes mellitus: Physiologically, preservation of C-peptide suggests that DPP-4 inhibitors may delay the autoimmune destruction of β-cells, a mechanism also observed in studies with GLP-1 agonists in patients with T1DM [11].